Detection of Antibodies to Gangliosides and Glycolipids in Various Intravenous Immunoglobulin (IVIg) Preparations

References

• Brannagan TH, III, Nagle K J, Lange D J, Rowland L P. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47: 674–677
   PubMed Web of Science ®Google Scholar
• Katirji B. Chronic relapsing axonal neuropathy responsive to intravenous immunoglobulin. Neurology 1997; 48: 1690–1694
   PubMed Web of Science ®Google Scholar
• Hahn A F, Bolton C F, Zochodne D, Feasby T E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067–1077
   PubMed Web of Science ®Google Scholar
• Dalakas M C. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997; 126: 721–730
   PubMed Web of Science ®Google Scholar
• Comi G., Nemni R, Amadio S, et al. Intravenous immunoglobulin treatment in multifocal motor neuropathy and other chronic immune-mediated neuropathies. Mult Scler 1997; 3: 93–97
   PubMedGoogle Scholar
• Castro L H, Ropper A H. Human immunoglobulin infusion in Guillain-Barré syndrome: Worsening during and after treatment. Neurology 1993; 43: 2729–2731
   PubMed Web of Science ®Google Scholar
• Siber G R, Werner B G, Halsey N A, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122: 204–211
   PubMed Web of Science ®Google Scholar
• Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIG preparations: In vivo study in naive mice. J Clin Immunol 1998; 18: 52–60
   PubMed Web of Science ®Google Scholar
• Vassilev T, Gelin C, Kaveri S V, Zilber M T, Boumsell L, Kazatchkine M D. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins IVIg). Clin Exp Immunol 1993; 92: 369–372
   PubMed Web of Science ®Google Scholar
• Lake D F, Landsperger W J, Bernstein R M, Schluter S F, Marchalonis J J. Characterization of autoantibodies directed against T cell receptors. Adv Exp Med Biol 1995; 383: 223–229
   PubMedGoogle Scholar
• Krause I, Hacham S, Gilburd B, et al. Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Clin Immunol Immunopathol 1995; 77: 229–235
   PubMedGoogle Scholar
• Willison H J. Ganglioside Autoantibodies. Autoantibodies, Peter J.B., Y. Shoenfeld. Elsevier Science B.V., Amsterdam, Netherlands 1996; 277–284
   Google Scholar
• Winer M A, Terryberry J W. Glycolipid (Excluding Ganglioside) Autoantibodies. Autoantibodies, J.B. Peter, Y. Shoenfeld. Elsevier Science B.V., Amsterdam, Netherlands 1996; 314–324
   Google Scholar
• Terryberry J, Sutjita M, Shoenfeld Y, et al. Myelin- and microbe-specific antibodies in Guillain-Barré syndrome. J Clin Lab Anal 1995; 9: 308–319
   PubMed Web of Science ®Google Scholar
• Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992; 10: 391–393
   PubMed Web of Science ®Google Scholar
• Carp HJA, Achiron R, Mashiach S, et al. Intravenous immunoglobulin in women with five or more abortions. Am J Reprod Immunol 1996; 35: 360–362
   PubMed Web of Science ®Google Scholar
• Aharon A, Levy Y, Bar Dayan Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997; 6: 408–411
   PubMed Web of Science ®Google Scholar
• Levy Y, George J, Langewitch P, et al. Novel aspects of IVIG treatment in autoimmune diseases. Proceedings of the XIX ILAR Congress of Rheumatology, pp. 456-458, Singapore, June, 8-131997
   Google Scholar
• Bakimer R, Gilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous gammaglobulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993; 69: 97–102
   PubMedGoogle Scholar
• Krause I, Blank M, Kopolovic J, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995; 22: 1068–1074
   PubMed Web of Science ®Google Scholar
• Counsell C, McLeod M, Grant R. Reversal of subacute paraneoplstic cerebellar syndrome with intravenous immunoglobulin. Neurology 1994; 44: 1184–1185
   PubMed Web of Science ®Google Scholar
• Ruiz J E, Kwak J Y, Baum L, et al. Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am J Reprod Immunol 1996; 35: 370–375
   PubMed Web of Science ®Google Scholar
• Kwak J Y, Kwak F M, Ainbinder S W, et al. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortion. Am J Reprod Immunol 1996; 35: 363–369
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Taniuchi S, Hattori K, et al. Effect of immunoglobulin therapy on phagocytosis by polymorphonuclear leukocytes in whole blood of neonates. Clin Exp Immunol 1997; 107: 435–439
   PubMed Web of Science ®Google Scholar
• Tenser R B, Hay K A, Aberg J A. Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. Arch Neurol 1993; 50: 417–420
   PubMedGoogle Scholar
• Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97: 865–869
   PubMed Web of Science ®Google Scholar
• Van Schaik I N, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vivo. J Clin Immunol 1992; 12: 325–334
   PubMed Web of Science ®Google Scholar
• Stohl W, Elliot J E. In vitro inhibition by intravenous immunoglobulin of T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol 1996; 79: 122–133
   PubMedGoogle Scholar
• Aukrust P, Muller F, Nordoy I, et al. Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo. Clin Exp Immunol 1997; 107: 50–56
   PubMed Web of Science ®Google Scholar
• Klaesson S, Tammik L, Markling L, et al. Inhibition of immunoglobulin production in vitro by IgG and F(ab')2 fragments but not the Fc portion. Scand J Immunol 1996; 43: 574–582
   PubMed Web of Science ®Google Scholar
• Miletic V D, Hester C G, Frank M M. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. J Immunol 1996; 156: 749–757
   PubMed Web of Science ®Google Scholar
• Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996; 104(Suppl. 1)21–25
   PubMed Web of Science ®Google Scholar
• Nachbaur D, Herold M, Eibl B, et al. A comparative study of the in vitro immunomodulatory activity of intact immunoglobulin (7S IVIG) F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 1997; 90: 212–218
   PubMed Web of Science ®Google Scholar
• Darville T, Milligan L B, Laffoon K K. Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect Immun 1997; 65: 366–372
   PubMed Web of Science ®Google Scholar
• Andersen L S, Petersen J, Svenson M, Bendtzen K. IgG for intravenous use autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: An in vitro phenomenon depending upon plastic adherence. Autoimmunity 1995; 22: 127–133
   PubMed Web of Science ®Google Scholar
• Toyoda M, Zhang X, Petrosian A, et al. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14: 178–189
   PubMed Web of Science ®Google Scholar
• Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180–186
   PubMedGoogle Scholar
• Ruiz de Souza V, Carreno M P, Kaveri S V, et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995; 25: 1267–1273
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y. Idiotypic network, pathogenic autoantibodies and autoimmunity. Clin Exp Immunol 1995; 101(Suppl. 1)26–28
   PubMedGoogle Scholar
• Yuki N, Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GMl antibody-mediated neuropathies. J Neurol Sci 1996; 139: 160–162
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y. Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. J Autoimmun 1996; 9: 235–239
   PubMed Web of Science ®Google Scholar
• Lundkvist I, Van Doorn P A, Vermeulen M, Brand A. Spontaneous recovery from Guillain-Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 1993; 67: 192–198
   PubMedGoogle Scholar
• Kiprov D D, Nachtigall R D, Weaver R C, et al. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. Am J Reprod Immunol 1996; 36: 228–234
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Mouton L, Spalter S H, et al. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 1996; 14(Suppl. 1)S9–S15
   PubMedGoogle Scholar
• Adebi M R, Hammarstrom L, Broome U, et al. Reduction in serum antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Clin Exp Immunol 1996; 105: 266–273
   PubMed Web of Science ®Google Scholar
• Antonelli A, Palla R, Casarosa L, et al. IgG, IgA, and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves' disease: Their in vitro solubilization by intravenous immunoglobulin. Clin Exp Rheumatol 1996; 14(Suppl. 15)S31–S35
   PubMedGoogle Scholar
• Balazs C, Molnar I. In vitro suppression of anti-TSH receptor autoantibody by autologous anti-idiotypic antibody in patients with Graves' disease. Acta Microbiol Immunol Hung 1995; 42: 163–169
   PubMedGoogle Scholar
• Bech E, Andersen H, Orntoft T F, et al. Association of IgM type anti-GMl antibodies and muscle strength in chronic acquired demyelinating polyneuropathy. Ann Neurol 1998; 43: 72–78
   PubMed Web of Science ®Google Scholar
• Azulay J P, Rihet P, Pouget J, et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 1997; 62: 391–394
   PubMed Web of Science ®Google Scholar
• Melero J, Tarrago D, Nunez-Rolden A, Sanchez B. Human polyreactive IgM monoclonal antibodies with blocking reactivity against self-reactive IgG. Scand J Immunol 1997; 45: 393–400
   PubMed Web of Science ®Google Scholar
• Galilli U. Alpha-galactosyl (anti-Gal) autoantibodies. Autoantibodies, J.B. Peter, Y. Shoenfeld. Elsevier Science B.V., Amsterdam, Netherlands 1996; 24–30
   Google Scholar
• Roux K H, Tankersley D L. A view of the human idiotypic repertoire: Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990; 144: 1387–1395
   PubMed Web of Science ®Google Scholar
• Romer J, Morgenthaler J J, Scherz R, Skvaril F. Characterization of various immunoglobulin preparations for intravenous application. Vox Sang 1982; 42: 62–73
   PubMed Web of Science ®Google Scholar
• Terryberry J W, Shoenfeld Y, Peter J B. Clinical utility of autoantibodies in Guillain-Barré syndrome and its variants. Clin Rev Allergy Immunol 1998; 16: 265–273
   PubMed Web of Science ®Google Scholar